Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Colon Cancer Clinical Trials

13 recruiting trials for Colon Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
13
Total Trials
13
Recruiting Now
2
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 1 / Phase 2NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC),...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 47412 locations
RECRUITINGPhase 1NCT07127874

A Study of PHN-012 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug...

Sponsor: Pheon TherapeuticsEnrolling: 16513 locations
RECRUITINGPhase 3NCT06293625

Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of...

Colon cancer (CC) is the 5th most common cancer worldwide. Standard care for locally advanced disease is surgical resection followed by 3-6 months of adjuvant chemotherapy (AC)...

Sponsor: Centre Hospitalier Universitaire DijonEnrolling: 1501 location
RECRUITINGPhase 3NCT06107920

Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy

The aim of this study is to determine whether chemotherapy prior to tumor removal (neoadjuvant chemotherapy), in patients undergoing treatment for colon cancer in occlusion (CCO),...

Sponsor: University Hospital, RouenEnrolling: 23220 locations
RECRUITINGNCT06715839

Target-specific immunoPET Imaging of Digestive System Carcinoma

The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of...

Sponsor: RenJi HospitalEnrolling: 4001 location
RECRUITINGPhase 1NCT05848739

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV...

Sponsor: Sapience TherapeuticsEnrolling: 13011 locations
RECRUITINGNCT05142033

Avera Cancer Sequencing and Analytics Protocol (ASAP)

The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare...

Sponsor: Avera McKennan Hospital & University Health CenterEnrolling: 250006 locations
RECRUITINGPhase 1 / Phase 2NCT06682793

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 24010 locations
RECRUITINGNCT05056077

Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)

This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors. Studies indicate...

Sponsor: University of California, San FranciscoEnrolling: 10001 location
RECRUITINGNCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal...

Sponsor: University of NebraskaEnrolling: 99999920 locations
RECRUITINGPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 1156 locations
RECRUITINGPhase 2NCT03175224

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET...

Sponsor: Apollomics Inc.Enrolling: 49720 locations
RECRUITINGNCT04916990

Improving Care for Rural Patients With Solid Tumors

This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment...

Sponsor: University of Colorado, DenverEnrolling: 32014 locations